Literature DB >> 26645605

CD4+ T-cell recovery with suppressive ART-induced rapid sequence evolution in hepatitis C virus envelope but not NS3.

Lin Liu1, David Nardo, Eric Li, Gary P Wang.   

Abstract

OBJECTIVES: CD4 T-cell depletion from HIV infection leads to a global decline in anti-hepatitis C virus (HCV) envelope neutralizing antibody (nAb) response, which may play a role in accelerating liver fibrosis. An increase in anti-HCV nAb titers has been reported during antiretroviral therapy (ART) but its impact on HCV remains poorly understood. The objective of this study is to determine the effects of ART on long-term HCV evolution. DESIGN AND METHODS: We examined HCV quasispecies structure and long-term evolution in HIV/HCV coinfected patients with ART-induced CD4 T-cell recovery, and compared with patients with CD4 T-cell depletion from delayed ART. We applied a single-variant sequencing (SVS) method to construct authentic viral quasispecies and compared sequence evolution in HCV envelope, the primary target for humoral immune responses, and NS3, a target for cellular immunity, between the two cohorts.
RESULTS: The SVS method corrected biases known to skew the proportions of viral variants, revealing authentic HCV quasispeices structures. We observed higher rates of HCV envelope sequence evolution in patients with ART-induced CD4 T-cell recovery, compared with patients with CD4 T-cell depletion from delayed ART (P = 0.03). Evolutionary rates for NS3 were considerably lower than the rates for envelope (P < 0.01), with no significant difference observed between the two groups.
CONCLUSION: ART-induced CD4 T-cell recovery results in rapid sequence evolution in HCV envelope, but not in NS3. These results suggest that suppressive ART disproportionally enhances HCV-specific humoral responses more than cellular responses, resulting in rapid sequence evolution in HCV envelope but not NS3.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26645605      PMCID: PMC4767613          DOI: 10.1097/QAD.0000000000000997

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  54 in total

1.  High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection.

Authors:  Alleluiah Rutebemberwa; Stuart C Ray; Jacquie Astemborski; Jordana Levine; Lin Liu; Kimberly A Dowd; Shalyn Clute; Changyu Wang; Alan Korman; Alessandro Sette; John Sidney; Drew M Pardoll; Andrea L Cox
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

2.  CD4+ T-Cell-Dependent Reduction in Hepatitis C Virus-Specific Neutralizing Antibody Responses After Coinfection With Human Immunodeficiency Virus.

Authors:  Justin R Bailey; Kimberly A Dowd; Anna E Snider; William O Osburn; Shruti H Mehta; Gregory D Kirk; David L Thomas; Stuart C Ray
Journal:  J Infect Dis       Date:  2015-03-09       Impact factor: 5.226

3.  Characterization of resistance mutations against HCV ketoamide protease inhibitors.

Authors:  Xiao Tong; Stephane Bogen; Robert Chase; V Girijavallabhan; Zhuyan Guo; F George Njoroge; Andrew Prongay; Anil Saksena; Angela Skelton; Ellen Xia; Robert Ralston
Journal:  Antiviral Res       Date:  2007-12-28       Impact factor: 5.970

4.  Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.

Authors:  Simone Susser; Christoph Welsch; Yalan Wang; Markus Zettler; Francisco S Domingues; Ursula Karey; Eric Hughes; Robert Ralston; Xiao Tong; Eva Herrmann; Stefan Zeuzem; Christoph Sarrazin
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

5.  Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.

Authors:  Mansun Law; Toshiaki Maruyama; Jamie Lewis; Erick Giang; Alexander W Tarr; Zania Stamataki; Pablo Gastaminza; Francis V Chisari; Ian M Jones; Robert I Fox; Jonathan K Ball; Jane A McKeating; Norman M Kneteman; Dennis R Burton
Journal:  Nat Med       Date:  2007-12-06       Impact factor: 53.440

6.  Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA.

Authors:  Takeshi Saito; David M Owen; Fuguo Jiang; Joseph Marcotrigiano; Michael Gale
Journal:  Nature       Date:  2008-06-11       Impact factor: 49.962

7.  Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.

Authors:  Doug J Bartels; Yi Zhou; Eileen Z Zhang; Michelle Marcial; Randal A Byrn; Thomas Pfeiffer; Ann M Tigges; Bambang S Adiwijaya; Chao Lin; Ann D Kwong; Tara L Kieffer
Journal:  J Infect Dis       Date:  2008-09-15       Impact factor: 5.226

Review 8.  Coinfection with HIV-1 and HCV--a one-two punch.

Authors:  Arthur Y Kim; Raymond T Chung
Journal:  Gastroenterology       Date:  2009-06-21       Impact factor: 22.682

9.  Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus.

Authors:  Kimberly A Dowd; Dale M Netski; Xiao-Hong Wang; Andrea L Cox; Stuart C Ray
Journal:  Gastroenterology       Date:  2009-03-17       Impact factor: 22.682

10.  Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.

Authors:  Thomas von Hahn; Joo Chun Yoon; Harvey Alter; Charles M Rice; Barbara Rehermann; Peter Balfe; Jane A McKeating
Journal:  Gastroenterology       Date:  2006-12-03       Impact factor: 22.682

View more
  1 in total

1.  Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV).

Authors:  Ashley N Brown; Lin Liu; Jaime L Rodriquez; Lisa Zhao; Layla Schuster; Eric Li; Gary P Wang; Michael N Neely; Walter Yamada; George L Drusano
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.